iSonea (ASX:ISN) has commenced commercial discussions with...

iSonea (ASX:ISN) has commenced commercial discussions with potential partners in regards to its AirSonea wireless asthma wheeze monitor and app.

This is based on its clinically validated Acoustic Respiratory Measurement technology, which underpins all its products.

AirSonea enables collaborative input from potential partenrs into the follow-up trial that focuses on the efficacy of AirSonea of managing asthma in children during and after an acute asthma attack.

This offers the pharmaceutical industry the opportunity to objectively evaluate different treatment modalities by providing a method of objective measuring of the frequency and severity of airway obstruction.